Libo Pharma Corp. (TPEX:7888)

Libo Pharma Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023
Selling, General & Admin	37.44	27.69	10.99
Research & Development	186.67	123.46	41.08
Operating Expenses	224.11	151.16	48.91
Operating Income	-224.11	-151.16	-48.91
Interest Expense	-0.05	-0.05	-0.07
Interest & Investment Income	1.95	2.51	2.06
Currency Exchange Gain (Loss)	0.27	0.9	0.51
Pretax Income	-221.94	-147.8	-46.41
Net Income	-221.94	-147.8	-46.41
Net Income to Common	-221.94	-147.8	-46.41
Shares Outstanding (Basic)	41	37	27
Shares Outstanding (Diluted)	41	37	27
Shares Change (YoY)	-	41.35%	-
EPS (Basic)	-5.43	-3.95	-1.75
EPS (Diluted)	-5.43	-3.95	-1.75
Free Cash Flow	-163.97	-119.84	-36.01
Free Cash Flow Per Share	-4.01	-3.20	-1.36
EBITDA	-202.7	-134.73	-45.1
D&A For EBITDA	21.41	16.43	3.81
EBIT	-224.11	-151.16	-48.91

Source: S&P Global Market Intelligence. Standard template. Financial Sources.